4-Amino-5-oxo-8-phenyl-5H-pyrido(2,3-D) pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours

A compound of formula I

• in which
• R6, R7 each, independently of one another, is H, A, Hal, OH, QA or CN,
• R8, R9 each, independently of one another, is H or A,
• Het1 is a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O or S atoms, in which optionally said heterocycle is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, OH, alkenyl having 2 to 6 C atoms, alkynyl having 2 to 6 C atoms, NO2, NH2, NHA, NA2, COOH, COOA, CN, —O-Het, —O-alkylene-Het, —O-alkylene-NR8R9, —NR8-alkylene-NR8R9, CONR8R9, —O-alkylene-NR8-alkylene-OR8 or carbonyl oxygen (═O),
• Het is a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O or S atoms, in which optionally said heterocycle is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOA, CN or carbonyl oxygen (═O),
• A is alkyl having 1 to 10 C atoms, in which 1-7H atoms optionally are replaced by F or chlorine,
• X, X′ each, independently of one another, is NH,
• Hal is F, Cl, Br or I;
• or
• physiologically acceptable salts, tautomers or stereoisomers of said compound or compounds of formula I or mixtures thereof in all ratios.